πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,444 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11312964

Compositions and methods for modulating growth hormone receptor expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11293025

Compositions and methods for modulating Ataxin 3 expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11291659

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Fulcrum Therapeutics, Inc. Β· Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11286291

Co-stimulatory domains for use in genetically-modified cells

Precision BioSciences, Inc. Β· Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11279768

Anti-cancer antibodies, combination therapies, and uses thereof

PRECISION BIOLOGICS, INC. Β· Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11278632

Engineered nucleases useful for treatment of hemophilia A

Precision BioSciences, Inc. Β· Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11278572

Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cel

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11278535

Compounds and their methods of use

PRAXIS PRECISION MEDICINES, INC. Β· Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11278529

Methods for treating aggression associated with Alzheimer's disease

OVID THERAPEUTICS INC. Β· Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11274305

Compositions and methods for in vivo excision of HIV-1 proviral DNA

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11274285

Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genom

Precision BioSciences, Inc. Β· Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11268096

Compounds for modulating Fc-epsilon-RI-beta expression and uses thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11268065

Genetically-modified cells comprising a modified human T cell receptor alpha constant regi

Precision BioSciences, Inc. Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11267845

Inhibitors of CD73-mediated immunosuppression

Arcus Biosciences, Inc. Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11266693

Nucleic acids encoding engineered meganucleases with recognition sequences found in the hu

Precision BioSciences, Inc. Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11261447

Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11261188

Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and cond

PRAXIS PRECISION MEDICINES, INC. Β· Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11260120

Immunogenic composition comprising a fusion peptide derived from superantigen toxoids

INTEGRATED BIOTHERAPEUTIC VACCINES, INC. Β· Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11260050

Combination of cotinine plus antioxidant for treatment-resistant depression and correction

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11254731

Viral vectors encoding recombinant FVIII variants with increased expression for gene thera

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11254725

Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11248039

Immunoglobulin single variable domain antibody against RSV prefusion F protein

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11241451

Modulators of IRF4 expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11236339

Modulation of GYS1 expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted